Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Report details first case of PML with ocrelizumab alone
Key clinical point: Clinicians have diagnosed progressive multifocal leukoencephalopathy (PML) in a patient who was treated with ocrelizumab and had not received other treatments for multiple sclerosis (MS).
Major finding: The first case of PML directly associated with ocrelizumab occurred in a 78-year-old male with primary progressive MS who received 2 years of ocrelizumab monotherapy and had not received prior immunomodulatory medication.
Study details: Case report.
Disclosures: An author of the study has received research support from MSD (Merck), Eisai, AbbVie, and Janssen.
Citation:
Sul J et al. AAN 2020. Abstract S29.001.